These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 2117799)

  • 1. Uses of orthoclone OKT3 for prophylaxis of rejection and induction in initial nonfunction in kidney transplantation.
    Kahana L; Ackermann J; Lefor W; Weinstein S; Wright C; DeQuesada A; Alveranga D; Baxter J; Shires D
    Transplant Proc; 1990 Aug; 22(4):1755-8. PubMed ID: 2117799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
    Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
    Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function.
    Cohen DJ; Benvenisty AI; Cianci J; Hardy MA
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):19-27. PubMed ID: 2510507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Orthoclone OKT3 monoclonal antibody to reverse acute renal allograft rejection unresponsive to treatment with conventional immunosuppressive regimens.
    Monaco A; Goldstein G; Barnes L
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):28-31. PubMed ID: 3105137
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison between prophylactic use of OKT3 and cyclosporine in cadaveric renal transplantation.
    De Pauw L; Abramowicz D; Goldman M; Vereerstraeten P; Kinnaert P; Toussaint C
    Transplant Proc; 1990 Aug; 22(4):1759-60. PubMed ID: 2117800
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunologic monitoring with Orthoclone OKT3 therapy.
    Schroeder TJ; First MR; Hurtubise PE; Marmer DJ; Martin DM; Mansour ME; Melvin DB
    J Heart Transplant; 1989; 8(5):371-80. PubMed ID: 2529358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with OKT3 and cyclosporine for acute allograft rejection.
    Schulak JA; Mayes JT; Hricik DE
    Transplant Proc; 1991 Aug; 23(4):2119-22. PubMed ID: 1908150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orthoclone OKT3 treatment of acute renal allograft rejection in patients receiving maintenance cyclosporine therapy.
    Hirsch RL; Layton PC; Barnes LA; Kremer AB; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):32-6. PubMed ID: 3105138
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
    Thistlethwaite JR; Heffron TG; Stuart JK; Buckingham M; Stuart FP
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orthoclone OKT3 monoclonal antibody reversal of hepatic and cardiac allograft rejection unresponsive to conventional immunosuppressive treatments.
    Kremer AB; Barnes L; Hirsch RL; Goldstein G
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):54-7. PubMed ID: 3105141
    [No Abstract]   [Full Text] [Related]  

  • 12. A U.S. clinical study of Orthoclone OKT3 in renal transplantation.
    Norman DJ; Shield CF; Barry J; Henell K; Funnell MB; Lemon J
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):21-7. PubMed ID: 3105136
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
    Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
    J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of steroid-resistant renal allograft rejection with OKT3 and plasmapheresis.
    Haberal M; Sert S; Gülay H; Arslan G; Bilgin N
    Transplant Proc; 1990 Aug; 22(4):1761-3. PubMed ID: 2117801
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
    J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quadruple immunosuppression: comparison of OKT3 and Minnesota antilymphocyte globulin.
    Light JA; Khawand N; Aquino A; Ali A; Korb S
    Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):10-3. PubMed ID: 2510505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pilot study on induction treatment with high-dose OKT3: preliminary observations in kidney transplantation.
    Welter HF; Illner WD; Schleibner S; Abendroth D; Hancke E; Groh J; Land W
    Transplant Proc; 1990 Oct; 22(5):2272. PubMed ID: 2120813
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical development of Orthoclone OKT3.
    Cosimi AB
    Transplant Proc; 1987 Apr; 19(2 Suppl 1):7-16. PubMed ID: 3105142
    [No Abstract]   [Full Text] [Related]  

  • 20. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
    Hegewald MG; O'Connell JB; Renlund DG; Lee HR; Burton NA; Karwande SV; Jones KW; Lassetter JE; Bristow MR
    J Heart Transplant; 1989; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.